A similar judgment could be leveled at HPV39 VLP which generated neutralizing antibodies against HPV59 and HPV68. These data suggest that a multivalent next generation vaccine could perhaps be optimized to generate antibodies capable of recognizing a wide array ABT-199 cell line of Alpha-7 and Alpha-9 HPV genotypes with a limited number of L1 VLP immunogens. Alternatively, these data could also be used to support the approach of a multivalent next generation vaccine that wholly relies on the generation of high

titer type-specific antibodies. A next generation HPV vaccine comprising multiple VLP, such as the V503 vaccine candidate [24], is likely to provide greater coverage than the current bivalent (Cervarix®) and quadrivalent (Gardasil®) HPV vaccines [46]. Two other

next generation VLP-based vaccine candidates may also be in the pipeline: one containing HPV16, HPV18, HPV31 and HPV45 VLP and another comprising HPV16, HPV18, HPV33 and HPV58 VLP [47]. There are significant cost implications for such vaccines though these may be Anti-diabetic Compound Library mitigated by observations that type-specific antibody titers following reduced dosing schedules of the current HPV vaccines were non-inferior to those generated under the standard three dose schedule [25], [26] and [27]. Fewer than three vaccine doses, however, may impact on the generation of cross-neutralizing antibodies [10] and [25] due to their reduced kinetics and the low levels found in the serum and genital secretions of vaccinees compared to vaccine type antibodies [10], [18], [19], [33] and [48]. Given the low and possibly transient levels of cross-neutralizing antibodies generated by immunization with VLP, a single dose of a multivalent vaccine may be sufficient to elicit appropriate high titer, type-specific antibodies against a range of incorporated genotypes. In summary,

these data clarify the extent of antigenic diversity of the major capsid proteins of HPV genotypes that segregate into the Alpha-7 and Alpha-9 species groups, have implications for the optimized composition of next generation HPV aminophylline vaccines based upon L1 VLP and contribute to our understanding of the immunogenicity of the major capsid protein of HPV. This work was supported by the UK Medical Research Council (grant number G0701217). We are indebted to Prof. John T. Schiller and Dr. Chris Buck (National Cancer Institute, Bethesda, U.S.A.) and Dr. H Faust and Prof. J. Dillner (Malmö University Hospital, Malmö, Sweden) for access to the majority of the pseudovirus clones used in this study. We thank GlaxoSmithKline Biologicals SA for the donation of VLP and AS04 for use in pilot formulation studies of the in house VLP preparations for the rabbit immunizations.